Search Results for "Pfizer Drug Tofaciti"
Matching Channels
Pfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have...
What is GENOTROPIN? GENOTROPIN (somatropin [rDNA origin] for injection) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference i...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in e...
Matching News
Pfizer ends development of hepatitis C drug filibuvir
Pfizer has scrapped plans to develop a drug for hepatitis C, a move that takes the pharmaceutical giant out of the competition for the next generation of treatments. Without any fanfare, Pfizer noted...
FDA holds up Pfizer’s rare disease drug tafamidis
The FDA has sent Pfizer a Complete Response Letter about its rare disease drug tafamidis meglumine. The US regulator is asking Pfizer for a second clinical study to establish ‘substantial evidence o...
Pfizer study: Arthritis pill beats standard drug
A late-stage study of Pfizer Inc.'s experimental drug for moderate-to-severe rheumatoid arthritis found it worked better than the standard treatment, Pfizer said Tuesday.Pfizer released limited result...
Could Tofacitinib Save Pfizer?
By Bio Vantage:In previous report Lipitor's expiration: how much will it impact Pfizer's revenue and earnings?, we discussed how Pfizer's (PFE) declining drug sales for key products (e.g. Lipitor) wou...
Pfizer’s breast cancer drug receives BTD from US FDA
The US Food and Drug Administration has awarded Breakthrough Therapy designation to Pfizer’s breast cancer drug. Following the news last week that Janssen’s leukaemia drug had received its third...
News Summary: Pfizer buys rights to OTC Nexium
HEARTBURN HEALER: AstraZeneca has sold fellow drugmaker Pfizer the global rights to market a nonprescription version of heartburn drug Nexium, which has annual sales of nearly $8 billlion, starting in...
Protalix extends Gaucher drug deal with Pfizer
Protalix BioTherapeutics Inc. said Thursday that it will continue to work with Pfizer Inc. to develop their Gaucher disease drug Elelyso.Protalix said it will continue to manage and fund active trial...
Pfizer to pay $55 million in drug misbranding case
The Justice Department says Pfizer Inc. will pay $55 million to resolve allegations that Wyeth LLC promoted the drug Protonix for uses that were not approved by the Food and Drug Administration. Pfiz...
Matching PubMed Articles
Lead Diversification 2: Application to P38, gMTP and lead compounds.
Lead Diversification is a new technology platform developed at Pfizer for the functionalization of drug molecules using C-H activation. We describe its application to some drug programs such as P38 an...
Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Response to "Drug Labels: A Flawed Source of Data for Studying Orphan Drug Approvals"
